Ayoub IM, Kolarova JD, Kantola RL, Radhakrishnan J, Wang S, Gazmuri RJ Zoniporide preserves left ventricular compliance during ventricular fibrillation and minimizes postresuscitation myocardial dysfunction through benefits on energy metabolism. Crit Care Med. 2007 Oct;35(10):2329-36.
Hosoya M, Nunoi H, Aoyama M, Kawasaki Y, Suzuki H Cytochrome c and tumor necrosis factor-alpha values in serum and cerebrospinal fluid of patients with influenza-associated encephalopathy. Pediatr Infect Dis J. 2005 May;24(5):467-70.
Jacobs S, Zuleika M, Mphansa T The Multiple Organ Dysfunction Score as a descriptor of patient outcome in septic shock compared with two other scoring systems. Crit Care Med. 1999 Apr;27(4):741-4.
Li X, Liu H, He X, Song Z Determination of cytochrome c in human serum and pharmaceutical injections using flow injection chemiluminescence. Appl Biochem Biotechnol. 2010 Feb;160(4):1065-73. doi: 10.1007/s12010-009-8598-8. Epub 2009 Apr 4.
Liu X, Xie W, Liu P, Duan M, Jia Z, Li W, Xu J Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sci. 2006 Apr 4;78(19):2255-64. Epub 2005 Dec 5.
Morley P Steady as a ROC: the Resuscitation Outcomes Consortium. Resuscitation. 2008 Aug;78(2):105-6. doi: 10.1016/j.resuscitation.2008.06.007.
Narula J, Arbustini E, Chandrashekhar Y, Schwaiger M Apoptosis and the systolic dysfunction in congestive heart failure. Story of apoptosis interruptus and zombie myocytes. Cardiol Clin. 2001 Feb;19(1):113-26. Review.
Petrosillo G, Ruggiero FM, Pistolese M, Paradies G Ca2+-induced reactive oxygen species production promotes cytochrome c release from rat liver mitochondria via mitochondrial permeability transition (MPT)-dependent and MPT-independent mechanisms: role of cardiolipin. J Biol Chem. 2004 Dec 17;279(51):53103-8. Epub 2004 Oct 8.
Radhakrishnan J, Ayoub IM, Gazmuri RJ Activation of caspase-3 may not contribute to postresuscitation myocardial dysfunction. Am J Physiol Heart Circ Physiol. 2009 Apr;296(4):H1164-74. doi: 10.1152/ajpheart.00338.2008. Epub 2009 Feb 20.
Radhakrishnan J, Kolarova JD, Ayoub IM, Gazmuri RJ AVE4454B--a novel sodium-hydrogen exchanger isoform-1 inhibitor--compared less effective than cariporide for resuscitation from cardiac arrest. Transl Res. 2011 Feb;157(2):71-80. doi: 10.1016/j.trsl.2010.11.004. Epub 2010 Dec 15.
Radhakrishnan J, Wang S, Ayoub IM, Kolarova JD, Levine RF, Gazmuri RJ Circulating levels of cytochrome c after resuscitation from cardiac arrest: a marker of mitochondrial injury and predictor of survival. Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H767-75. Epub 2006 Oct 13.
von Harsdorf R, Li PF, Dietz R Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation. 1999 Jun 8;99(22):2934-41.
Yan S, Xu X, Sheng Y, Sun H, Wu J, Tang L Disposable biosensor based on Au nanoparticles-modified CdS nanorod arrays for detection cytochrome c. J Nanosci Nanotechnol. 2011 Dec;11(12):10320-3.
Zager RA, Johnson AC, Hanson SY Proximal tubular cytochrome c efflux: determinant, and potential marker, of mitochondrial injury. Kidney Int. 2004 Jun;65(6):2123-34.
Zou H, Li Y, Liu X, Wang X An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 1999 Apr 23;274(17):11549-56.
Plasma Cytochrome c as Biomarker of Traumatic Injury and Predictor of Outcome
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.